A major obstacle to successful chemotherapy with many cancer chemotherapeutics and particularly with anthracyclines, vinca alkaloid, anthracenediones and epipodophyllotoxins is the emergence of multidrug resistance (MDR) observed in experimental conditions as well as in patients (Goldstein et al., 1989; Rothenberger & Ling, 1989) . This phenomenon has prompted extensive efforts to search for chemotherapeutic treatments active on MDR tumours.
Tumour cells presenting the MDR phenotype (Kaye, 1988; Beck, 1987) are resistant to several classes of drugs because of the presence of high levels of pl70 (Endicott et al., 1989) , a membrane glycoprotein able to recognise and extrude the cross-resistant compounds before cytotoxic intracellular concentrations can be reached.
The two most explored approaches for overcoming MDR are the combination of p170-inhibitors (the so-called resistance modulators) with cross-resistant drugs (Beck, 1990) , or the synthesis of new analogues not extruded by p170 (Odaini et al., 1986; Watanabe et al., 1988; Coley et al., 1990; Grandi et al., 1990a,b) . In both cases, activity on MDR cells is obtained because drugs have been made able to reach cytotoxic intracellular levels. Anthracyclines are an important class of clinically effective anti-tumour drugs, and much effort has been devoted to collecting structure-activity data in relation to their effect on MDR cells (Grandi et al., 1990b) .
Thus, several derivatives of doxorubicin (DX) or daunorubicin have been synthesised and found to be equally effective in vitro on sensitive and MDR cells. Among these, one of the most promising appears to be the class of morpholino anthracyclines, which were found to possess high effectiveness in vivo, as well as in vitro, on DX-resistant tumours (Watanabe et al., 1988; Grandi et al., 1990b) .
In this paper, we report the pattern of anti-tumour activity of FCE 23762 on a panel of murine leukaemias and murine and human solid tumours.
FCE 23762 is a new DX derivative bearing a methoxy morpholinyl group at position 3' of the sugar moiety. Preliminary results on its cytotoxic activity, intracellular accumulation on LoVo and LoVo/DX human colon adenocarcinoma cells and anti-tumour activity have already been presented (Grandi et al., 1990b (Grandi et al., 1990a Melphalan (L-PAM) (Sigma Chemical Co., St Louis, IL, USA) was weighed and dissolved in 1 N HCI (20 mg ml-'), and further dissolved in H20; cis-platinum (cDDP) (Farmitalia C.Erba, Milan, Italy) was weighed and dissolved in water; 1,3 bis (2-chloroethyl)-l-nitrosourea (BCNU; Simes SpA, Vicenza, Italy) was weighed and dissolved in ethanol and H20.
Animals
Inbred DBA/2, C57B1/6, C3H/He, first generation hybrid C57B1/6 x DBA/2F1 (BD2F1) and BALB/c x DBA/2F1 (CD2F1) adult mice of both sexes were used to evaluate the anti-tumour activity.
In experiments with human tumour xenografts, adult female Swiss/nu/nu mice were employed. All animals were supplied by Charles River (Calco, Como, Italy). The conventional mice were 2-3-months old, weighed [20] [21] [22] (Di Marco et al., 1972) .
The murine Colon 38 tumour was transplanted s.c. in C57B1 /6 mice using 15 -20 mg of tumour brei. MX1 human mammary carcinoma and CX1 human colon carcinoma (NCI, NIH, Bethesda, MD, USA), N592 human small cell lung carcinoma and A549 lung adenocarcinoma (ATCC catalogue), LoVo and LoVo/DX colon carcinoma (Grandi et al., 1986) were transplanted s.c. in athymic mice using 15-20 mg of tumour brei.
Drug administration
All drug solutions were prepared immediately before use. Treatment was administered i.p., i.v. or orally (by stomach tube) in a volume of 10 ml kg-' of body weight. Treatment schedules are reported in the Results.
Evaluation of anti-tumour activity and toxicity
In experiments in leukaemia models, drug activity was determined by comparing the median survival time (MST) of the treated group with that of the control group, and results are expressed as %T/C, where:
%T/C= MST of treated group x 100
MST of control group In experiments with solid tumours, primary tumour growth was assessed by caliper measurement, and tumour weight was estimated according to Geran et al. (1972) . The anti-tumour effect was determined by change of tumour weights of the treated group and that of the control group on a given day. The number of long-term survivors refers to mice surviving at the end of the experiment: >60 days from tumour implant for leukaemias, > 120 days from tumour implant for murine solid tumours. For human solid tumours, the tumour-free mice 60 days after tumour implant are considered cured mice.
Toxicity was evaluated on the basis of the gross autopsy findings and the weight loss. In the experiments on solid tumours, tumour-bearing mice were observed for 4 months after the beginning of treatment for evaluation of lethality.
Mice are considered to have died of toxicity when death occurred before the controls, or when significant body weight loss and/or spleen and liver size reductions were observed.
Results
The structure of FCE 23762 is reported in Figure 1 . The lipophilicity of the compound was evaluated by means of a direct RP-HPLC (reverse phase-high performance liquid chromatography) method (Facchetti et al., 1991) and lipophilicity is expressed as the capacity factor evaluated at 0% of the organic phase (log K.) which is the retention index. At pH 7, FCE 23762 (log KO = 2.768) is more lipophilic than DX (log K,o = 0.795). Table I .
Against i.p. implanted P388 leukaemia, FCE 23762 and DX presented equivalent efficacy with a %T/C value of 243 and 290 at the optimal dose of 0.15 mg kg-' and 15 mg kg-l respectively. Against the two ascitic DX-resistant P388 sublines, the compound maintained activity with a %T/C value of 155 and 165, whereas DX was completely ineffective. Equivalent results were observed after i.v. and oral treatment against disseminated P388 and P388/DX leukaemias; FCE 23762 was in fact able to increase the survival time in all three models at the optimal dose of 0.092-0.11 mg kg-' and 0.15mgkg-' after i.v. and oral administration respectively. In the evaluation of the anti-tumour activity by the oral route, the comparison with DX is not reported. DX is in fact inactive by this route (Barbieri et al., 1987) . Table II demonstrates that the efficacy observed against i.p. or i.v. injected P388/DX leukaemia is maintained when cells are implanted subcutaneously. In fact tumour inhibition values of 90% and 85% were observed with the two tested treatment schedules; this activity was also reflected by a remarkable increase in the survival time. The two schedules utilised appear to be equally effective. This was also observed against disseminated P388/DX leukaemia where different repeated treatment schedules were assayed, obtaining antitumour activity equivalent to that observed after single administration (data not shown).
Because of the high lipophilicity of the compound, we investigated the activity of FCE 23762 against intracranially implanted P388 leukaemia (Table III) . In this particular model, we utilised BCNU as positive control. The drug given as single i.v. treatment was ineffective in increasing the survival time of mice; this result representing a possible indication that the compound does not cross the blood-brain barrier.
The anti-tumour activity of FCE 23762 was also explored against disseminated L1210 murine leukaemias sensitive and Tables VII and VIII. Table VII reports results obtained on a human mammary carcinoma, MX-1 and two lung tumours, N592 (small cell carcinoma) and A549 (adenocarcinoma).
The compound shows better efficacy than DX on MX1 mammary carcinoma, both after i.v. and oral administrations, giving a 99% reduction of tumour growth (%TI) with 90% of cured mice. Better efficacy in comparison with DX was also observed on N592 small cell lung carcinoma (%TI 89 vs 55), whereas both compounds were marginally effective on A549 adenocarcinoma (%TI 29 and 31). Table VIII presents the results obtained testing the activity of FCE 23762 on two human colon models, CX-l and LoVo, and the derived DX-resistant tumour, LoVo/DX. In the experimental conditions investigated, no anti-tumour activity 0/9 aTumour cells were inoculated at day 0. Treatment was started when the tumour was palpable. bMedian survival time of treated mice/median survival time of controls x 100. cThe percentage of tumour growth inhibition was calculated in respect to controls 1 week after tumour cell transplantation (day 0). dNumber of toxic deaths/number of mice, evaluated in tumour bearing mice. In all tested models, the major toxic effects observed after FCE 23762 treatment were body weight loss and organs reduction, in particular spleen and liver, these being the classic toxic effects of anthracyclines.
Discussion
This report presents the pattern of anti-tumour activity of FCE 23762, a novel derivative of DX bearing the methoxymorpholinyl group at position 3' of the sugar moiety.
The high lipophilicity of the molecule confers to FCE 23762 the characteristic of also being effective after oral administration; with this route, the optimal doses were between 1.5 and 2-fold higher than after i.v. administration. In contrast with previous observations on another morpholino derivative MX-2 (Izumoto et al., 1990) which is also highly lipophilic, FCE 23762 is inactive on intracranially implanted P388 leukaemia, this finding pointing to the possibility that the compound does not pass the blood-brain barrier.
Lipophilicity presumably also plays a role in the observed efficacy of FCE 23762 on DX-resistant cells in vitro and in vivo. In fact, anthracyclines more lipophilic than DX or DNR are generally more active on MDR cells (Facchetti et al., 1991) and are able to reach higher intracellular concentrations. Among these, FCE 23762 was shown to accumulate at high levels in all tested tumour cell lines, both sensitive and expressing the MDR phenotype (Grandi et al., 1990b) . Another factor to be taken into consideration is, however, the possible lower affinity to p170 of this class of compounds.
The results presented in this report indicate a consistent efficacy of FCE 23762 on DX-resistant P388 leukaemia cells implanted at different sites and with different routes of administration. This lack of cross-resistance to DX is also confirmed on two solid human tumour models, LoVo and LoVo/DX, where treatment with the compound was similarly effective, although at borderline levels of efficacy. Similar results were obtained on a murine fibrosarcoma model UV-2337 sensitive and resistant to DX (Giavazzi, in preparation) .
FCE 23762 was also effective on L1210 murine leukaemia and on two L1210 sublines resistant to L-PAM and cDDP, in the latter showing an activity equivalent to that seen on the wild-type line.
On solid tumours models FCE 23762 was able to inhibit tumour growth on different systems, with remarkable efficacy on MTV mammary carcinoma, M5076 murine reticulosarcoma, N592 human small cell lung cancer and MX-1 human mammary carcinoma. In this last model the drug was consistently more effective than DX, with an elevated number of mice surviving tumour-free after >60 days.
FCE 23762 differs from most anthracyclines in being activated to a highly potent metabolite(s) when injected in vivo. This is suggested by the finding that FCE 23762 is only 3-4 fold more cytotoxic than DX in vitro, whereas it is > 80 fold more potent when administered to mice (Grandi et al., 1990b) . This contention is reinforced by the recent report of Lau et al. (1991) , describing FCE 23762 being metabolised in vitro in the presence of human liver microsomes to a highly cytotoxic metabolite(s) able to alkylate DNA. Notwithstanding this possible alkylating activity, however, FCE 23762 maintains anti-tumour efficacy on L1210 leukaemias resistant to cDDP and L-PAM. The structure of the metabolite(s) is under active investigation.
The toxicity observed after treatment with FCE 23762 are those typical of classic anthracyclines with a low therapeutic index at the treatment schedules employed. We are now setting up a sensitive enough analytical method to evaluate the plasma AUC (area under curve) at the therapeutic and toxic doses, with the objective of identifying the best treatment schedules. However, because of its efficacy in vitro and in vivo on MDR tumour cells and pattern of anti-tumour activity in the tested models, as well as its unusual mode of action, this compound is recommended for clinical testing.
